RxDoctor Payments Data

Donald Wolfram, MD

Family Medicine · Bridgman, MINPI 1669499257

Payments from drug & device makers

$343in general payments, 2019–2025

Across 10 payments — averaging $34.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$102
  • GSK$77
  • E.r. Squibb & Sons, L.L.C.$57
  • Novo Nordisk$43
  • Takeda Pharmaceuticals U.S.A., Inc.$27
  • Pfizer$23
  • plus $12 from 1 others

What the payments were for

  • Food & beverage$33698%
  • Education$72%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca1$102
GSK1$77
E.r. Squibb & Sons, L.L.C.1$57
Novo Nordisk3$43
Takeda Pharmaceuticals U.S.A., Inc.2$27
Pfizer1$23
Circassia Inc.1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$343 in reported general payments places this provider in the 50th percentile of 3,945 family medicine providers in Michigan.

See all family medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$76,352
Medicare patients
388
Services billed
714

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban335$104,743
XareltoRivaroxaban63$19,149
TrulicityDulaglutide51$18,912
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$10,240
MyrbetriqMirabegron25$9,121
JanuviaSitagliptin Phosphate30$9,080
Serevent DiskusSalmeterol Xinafoate11$4,834
FarxigaDapagliflozin Propanediol22$4,643
Memantine Hcl89$4,553
Sertraline Hcl312$4,357
Atorvastatin Calcium425$4,208
Potassium Chloride333$3,821
ArexvyRsvpref3 Antigen/As01e/Pf12$3,793
Klor-ConPotassium Chloride11$3,306
Levothyroxine Sodium327$2,871

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$23$104,743335 claims
GSKTrelegy Ellipta, Arexvy$77$14,03328 claims
AstraZenecaFarxiga$102$4,64322 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 3,945 family medicine providers in Michigan.

Other family medicine in Bridgman

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →